文献速递淋巴瘤

原发中枢神经系统淋巴瘤的清髓性与非清髓性巩固治疗比较:Alliance 51101研究结果

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.
PubMed 文献 · Blood Adv · 2024-01-01

该随机2期试验在美国Alliance癌症合作组开展,比较原发中枢神经系统淋巴瘤诱导治疗后清髓性巩固联合自体干细胞移植与非清髓性巩固的疗效。113例患者随机,108例可评估,清髓组2年无进展生存率高于非清髓组(73% vs 51%,P=0.02),但以巩固治疗开始为界标的分析中两组无显著差异(86% vs 71%,P=0.21)。

要点

  • 清髓组2年无进展生存率73% vs 非清髓组51%(P=0.02),但界标分析无显著差异。
  • 非清髓组诱导期间疾病进展或死亡比例更高(28% vs 11%,P=0.05)。
  • 两种巩固策略均显示鼓舞人心的疗效,毒性特征相似。

核心结论

  • 两种巩固策略均产生鼓舞人心的疗效且毒性特征相似,但清髓性巩固组2年无进展生存率高于非清髓组(73% vs 51%,P=0.02)。
  • 以巩固治疗开始为界标的事后分析显示,完成巩固治疗者的2年无进展生存率在两组间无显著差异(86% vs 71%,P=0.21)。

研究设计与样本

  • 美国Alliance癌症合作组开展的随机2期临床试验,比较诱导治疗后清髓性巩固联合自体干细胞移植与非清髓性巩固。
  • 入组18至75岁新诊断原发中枢神经系统淋巴瘤患者,1:1随机分配。
  • 诱导方案为甲氨蝶呤、替莫唑胺、利妥昔单抗和阿糖胞苷。
  • 清髓性巩固为塞替派联合卡莫司汀及自体干细胞救援;非清髓性巩固为输注依托泊苷联合阿糖胞苷。
  • 共113例患者随机,108例可评估(每组54例);36例接受自体干细胞移植,34例接受非清髓性巩固。

主要发现

  • 非清髓组诱导期间疾病进展或死亡比例高于清髓组(28% vs 11%,P=0.05)。
  • 清髓组估计2年无进展生存率高于非清髓组(73% vs 51%,P=0.02)。
  • 以巩固治疗开始为界标的计划次要分析显示,完成巩固治疗者2年无进展生存率两组无显著差异(86% vs 71%,P=0.21)。
  • 两种巩固策略毒性特征相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although it is evident that standard-dose whole-brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We performed a randomized phase 2 clinical trial via the US Alliance cancer cooperative group to compare myeloablative consolidation supported by autologous stem cell transplantation with nonmyeloablative consolidation after induction therapy for PCNSL. To our knowledge, this is the first randomized trial to be initiated that eliminates whole-brain radiotherapy as a consolidative approach in newly diagnosed PCNSL. Patients aged 18 to 75 years were randomly assigned in a 1:1 manner to induction therapy (methotrexate, temozolomide, rituximab, and cytarabine) followed by consolidation with either thiotepa plus carmustine and autologous stem cell rescue vs induction followed by nonmyeloablative, infusional etoposide plus cytarabine. The primary end point was progression-free survival (PFS). A total of 113 patients were randomized, and 108 (54 in each arm) were evaluable. More patients in the nonmyeloablative arm experienced progressive disease or death during induction (28% vs 11%; P = .05). Thirty-six patients received autologous stem cell transplant, and 34 received nonmyeloablative consolidation. The estimated 2-year PFS was higher in the myeloablative vs nonmyeloablative arm (73% vs 51%; P = .02). However, a planned secondary analysis, landmarked at start of the consolidation, revealed that the estimated 2-year PFS in those who completed consolidation therapy was not significantly different between the arms (86% vs 71%; P = .21). Both consolidative strategies yielded encouraging efficacy and similar toxicity profiles. This trial was registered at www.clininicals.gov as #NCT01511562.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Batchelor TT, Giri S, Ruppert AS, et al. Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Blood Adv. 2024. PMID: 38598710. doi:10.1182/bloodadvances.2023011657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。